Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
IMTX
Strong SellImmatics N.V. · Healthcare · Germany · $1.2B · Avg Vol: $5M/d
COMPANY DESCRIPTION
Immatics N.V. is a clinical-stage biopharmaceutical company dedicated to developing highly potent and selective T-cell receptor (TCR)-based immunotherapies for cancer, including adoptive cell therapies (ACT) and bispecific TCRs (TCER®). The company leverages its proprietary XPRESIDENT® target discovery platform to identify novel tumor-associated peptides, enhancing the precision of its therapeutic candidates. Its competitive edge lies in its innovative approach to targeting solid tumors with engineered T-cells and bispecific molecules, aiming to overcome current limitations in cancer immunotherapy.
FINANCIAL SUMMARY (USD)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | 200.3M | 62.6M | 180.6M | 55.9M | -34.6% | 48.7M | 46.3M | 39.4M | -16.1% |
| EPS | -1.48 | 0.65 | -1.37 | 0.16 | -1.87 | -50.0% | -1.86 | -2.42 | -2.43 | — |
| Shares | — | 76.7M | 84.7M | 121.6M | 134.1M | +74.9% | 149.6M | — | — | — |
| Debt | — | 16.9M | 17.8M | 18.8M | 18.1M | 2.4% | 17.0M | — | — | — |
| Equity | — | 235.6M | 252.2M | 666.1M | 560.9M | 33.5% | — | — | — | — |
| Op CF | — | 116.0M | 21.1M | -183.1M | -204.7M | -81.8% | -240.2M | — | — | — |
| Inv CF | — | -243.1M | -36.4M | -176.6M | 237.3M | — | — | — | — | — |
| Fin CF | — | 143.3M | 97.9M | 370.4M | 112.8M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of IMTX are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| IMTX | Immatics N.V.(you) | $1.2B | 11 | Strong Sell |
| VRXA | Veraxa Biotech AG | $252M | 1 | Strong Sell |
| FYB.DE | Formycon AG | $380M | 36 | Hold |
| IFRX | InflaRx N.V. | $302M | 39 | Hold |
| BNTX | BioNTech SE | $28.3B | 28 | Sell |
| EVT.DE | Evotec SE | $679M | 20 | Sell |
| NNNN | Anbio Biotechnology | $347M | 18 | Strong Sell |
| GXI.DE | Gerresheimer AG | $1.1B | 56 | Hold |
| QUCY | Quantum Cyber N.V. | $110M | 21 | Sell |
| EUZ.DE | Eckert & Ziegler SE | $962M | 79 | Buy |
Peer medians: ROE 7.2% · P/E 16.7x · Gross margin 45.7%